

# China Insurance

## Raised cap for insurer's equity asset allocation could unleash max. RMB 1.7tn to stock market

The NFRA announced to raise the cap for Chinese insurers' equity asset allocation ratio corresponding to the comprehensive solvency ratio (CSR) by 5% for whose CSR ranging from (150%, 200%), (250%, 300%) and above 350% ([link](#)). The financial regulator eased equity investment upside for Chinese insurers to broaden incremental capital injection to the real economy in joint with other efforts to shore up the market sentiment, in our view. From a top-down perspective, we reckon the action could bring RMB1.66tn incremental funds to the stock market if the industry expanded the equity allocation to the upper limit of 30% of total insurance funds by end-FY24. For listed peers, we see the action could raise equity investment upside for Ping An Life, CPIC Group, Taiping Life, PICC Group, and PICC Life by 5% to 30%/40%/40%/40%/40% based on the companies' CSR in FY24. Core equities, incl. stocks and equity funds, accounted for 9%-18% of investment assets amid listed peers, of which OCI stocks significantly increased showcasing the emphasis on high-yield stock strategy. Looking ahead, we regard the key concern for insurers to level up equity investment was due to capital consumption, and expect to see continued optimization on solvency measurement, as disclosed in Sep 23 ([link](#)).

- **Three pivots to boost equity capital injection.** The notice promoted three pivots including 1) simplifying regulatory standards for insurers' equity asset allocation to five groups (prev. eight groups), and raise the upper limit of equity investment corresponding to the comprehensive solvency ratio by 5%, for those ranging from (150%, 200%), (250%, 300%) and above 350% ([Fig.2](#)); 2) allowing insurance funds to increase investment in venture capital funds and expand the concentration rate on a single paid-in size to no more than 30% (prev.20%); and 3) easing the standards for personal tax-deferred pension insurance accounts, whose investment ratio would no longer be separately calculated. In 4Q24, insurance funds amounted to RMB33.26tn, with industry CSR at 199.4%, allowing for a max. 30% equity investment (prev.25%). **We expect the raised cap to bring RMB1.66tn incremental funds to stock market, if the upper limit of 30% were to be reached.**
- **Listed peers allow for max. 30%-40% equity asset allocation.** The action will raise the upper limit of equity investment for Ping An Life, CPIC, Taiping Life, PICC Group, and PICC Life by 5% to 30%/40%/40%/40%/40% based on the CSR in FY24, whilst others' remained at 30% ([Fig.3](#)). This change can generate RMB 619bn incremental funds to the stock market if the cap was to reach, based on our estimate. **Looking ahead, we see ample room for improvement on core equities**, which made up 9%-18% of total investment assets among listed peers, **esp. in OCI stocks which surged to comprise 1%-5% by FY24.** The ranking of core equities was NCI (18.3%) > Taiping (13.7%) > Sunshine (13.3%) > PICC P&C (12.7%) > CPIC (11.3%) > China Life (10.8%) > Ping An (10.0%) > PICC Group (8.9%) > Zhong An (6.0%). OCI stocks surged more than four-/three-fold for NCI and China Life ([Fig.5](#)).
- **Valuation.** The sector is trading at 0.10x-0.48x FY25E P/EV and 0.46x-1.02x FY25E P/B, with an avg. yield at 6%. We view the easing action of the NFRA to raise cap for insurers' equity asset allocations as a step-up for broadening equity capital injection into the real economy. Looking ahead, **we remain positive on insurers' increasing allocation to high-yield stocks under FVOCI amid a low interest rate environment, whilst the key for equity increase is still on capital consumption.** Maintain sector OUTPERFORM. Key risks include prolonged low interest rate; heightened equity fluctuations, etc.

**OUTPERFORM**  
(Maintain)

### China Insurance Sector

#### Nika MA

(852) 3900 0805

nikama@cmbi.com.hk

#### Related Reports:

1. China Insurance - 4Q24 insurance funds: industry financial rate of return extended rally in a five-quarter streak, Feb 25, 2025 ([link](#))
2. China Insurance - 11/12M Monthly: Life sales diverged during the jumpstart; P&C softened by non-auto slowdown, 21 Jan, 2025 ([link](#))
3. China Insurance - 10M24 Monthly: Life premium retreated as expected, P&C grew with auto sales momentum, Nov 19, 2024 ([link](#))
4. China Insurance - 9M24 Monthly: Life growth normalized with highlights; P&C expected to see better UW profit, Oct 21, 2024 ([link](#))
5. China Insurance - 8M24 Monthly: Life jumped on top of low base; P&C top players rebounded in growth, Sep 23, 2024 ([link](#))
6. China Insurance - 7M24 Monthly: Life momentum kept strong; P&C edged up by auto & non-auto rebounds, Aug 20, 2024 ([link](#))
7. China Insurance - Insurance funds: Life/P&C diverged in allocation; financial yields marginally recovered in 2Q, Aug 14, 2024 ([link](#))
8. China Insurance - 6M24 monthly: Life prints better-than-expected on high base; P&C dragged by auto sales, Jul 23, 2024 ([link](#))
9. China Insurance - 5M24 Monthly: life growth stayed resilient; P&C auto premiums sequentially rebounded, Jun 19, 2024 ([link](#))
10. 中国保险行业 - 路演反馈: 政策催化下的弹性拉升可否持续? Jun 5, 2024 ([link](#))
11. China Insurance - 4M24 life diverged in face of high base; P&C top players dragged by non-auto, May 20, 2024 ([link](#))

**Fig. 1 The upper limit of equity asset allocation for insurance companies, from 2020/07**

Comprehensive solvency ratio (%)	The upper limit of total equity assets / total assets (%)
CSR < 100%	10.0%
100% ≤ CSR < 150%	20.0%
<b>150% ≤ CSR &lt; 200%</b>	<b>25.0%</b>
200% ≤ CSR < 250%	30.0%
<b>250% ≤ CSR &lt; 300%</b>	<b>35.0%</b>
300% ≤ CSR < 350%	40.0%
<b>CSR ≥ 350%</b>	<b>45.0%</b>

Source: The NFRA, CMBIGM

**Fig. 2 The upper limit of equity asset allocation for insurance companies, 2025/04 onwards**

Comprehensive Solvency ratio (%)	The upper limit of total equity assets / total assets (%)
< 100%	10%
100% ≤ CSR < 150%	20%
150% ≤ CSR < 250%	30.0%
250% ≤ CSR < 350%	40.0%
CSR ≥ 350%	50.0%

Source: The NFRA, CMBIGM


**Fig. 3 The upper limit of equity asset allocation change for listed insurers, FY24**

Companies	Comprehensive Solvency %	Upper limit of equity assets, Before change (%)	Upper limit of equity assets, Post-change (%)	Chg. (pct)	Potential incremental funds (RMB bn)
China Life	207.76%	30.0%	30.0%	0.00	0.0
Ping An Group	204.06%	30.0%	30.0%	0.00	0.0
<b>Ping An Life</b>	<b>189.19%</b>	<b>25.0%</b>	<b>30.0%</b>	<b>5.00</b>	<b>282.7</b>
Ping An P&C	205.30%	30.0%	30.0%	0.00	0.0
<b>CPIC Group</b>	<b>255.61%</b>	<b>35.0%</b>	<b>40.0%</b>	<b>5.00</b>	<b>141.7</b>
CPIC Life	210.28%	30.0%	30.0%	0.00	0.0
CPIC P&C	221.96%	30.0%	30.0%	0.00	0.0
New China Life	217.55%	30.0%	30.0%	0.00	0.0
China Taiping					
<b>Taiping Life</b>	<b>298.14%</b>	<b>35.0%</b>	<b>40.0%</b>	<b>5.00</b>	<b>69.4</b>
Taiping P&C	237.29%	30.0%	30.0%	0.00	0.0
<b>PICC Group</b>	<b>280.79%</b>	<b>35.0%</b>	<b>40.0%</b>	<b>5.00</b>	<b>88.3</b>
<b>PICC Life</b>	<b>275.41%</b>	<b>35.0%</b>	<b>40.0%</b>	<b>5.00</b>	<b>37.0</b>
PICC P&C	232.60%	30.0%	30.0%	0.00	0.0
ZhongAn	227.45%	30.0%	30.0%	0.00	0.0
Sunshine Group	227.18%	30.0%	30.0%	0.00	0.0
Sunshine Life	206.15%	30.0%	30.0%	0.00	0.0
Sunshine P&C	233.30%	30.0%	30.0%	0.00	0.0
<b>Total</b>					<b>619.3</b>
<b>Industry</b>	<b>199.40%</b>	<b>25.0%</b>	<b>30.0%</b>	<b>5.00</b>	<b>1,662.9</b>

Source: The NFRA, CMBIGM estimates | Note: Taiping Group did not disclose FY24 comprehensive solvency ratio.


## Focus Charts

**Fig 4: FVOCI stocks as a % of insurance funds, FY24**




Source: Company data, CMBIGM

**Fig 5: FVOCI stocks and YoY change, FY24**




Source: Company data, CMBIGM

**Fig 6: Core equities as a % of insurance funds, FY24**



Source: Company data, CMBIGM

**Fig 7: Stocks and equity funds as a % of insurance funds**



Source: Company data, CMBIGM

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.